News

Advance Care Planning 101 for Patients with Brain Tumors In the middle of your craniotomy, your neurosurgeon is tasked with making a critical yet unexpected decision. They consult with your loved ones in the waiting room. Thankfully, you had designated a health care proxy before surgery, and they made an informed decision based on the advance directive you signed. You wake up relieved to […] March 29, 2023

World Class Hospitals Join DNA Damage Response Consortium to Bring Forward New Treatments for Adults and Children with Brain Cancer Researchers from St. Jude Children’s Research Hospital, NYU, UCSF, and the University of Minnesota join National Brain Tumor Society and Yale-led Initiative   Today, the National Brain Tumor Society (NBTS), in partnership with Yale Cancer Center, announced new partners for its DNA Damage Response Consortium. Joining the initiative are world-class experts in adult and pediatric neuro-oncology […] March 28, 2023

Neuro-oncologist Advocates for Brain Tumor Community at Head to the Hill After three years of attending Head to the Hill virtually due to the pandemic, neuro-oncologist Dr. Nicholas Blondin is counting down the days to the event’s return in person to Capitol Hill this May 8-9. As a neuro-oncologist and the lead principal investigator of GBM AGILE at Yale Cancer Center and Smilow Cancer Hospital, Dr. […] March 27, 2023

Patient Defends Dissertation with Unwavering Resilience After Brain Tumor Diagnosis Christina E. entered the lobby of the 2022 San Diego Comic-Con to reunite with friends for the seventh time in nine years. A lot had changed since she’d last attended the largest annual comic and pop culture convention in the world in 2019:  a pandemic, for one, a career change, and her ability to speak […] March 22, 2023

New Approval of Treatment for Young Children with Certain Brain Cancers On March 16, 2023, the U.S. Food and Drug Administration approved a new treatment combination that will now be available as an option for pediatric patients 1 year of age and older with low-grade glioma (LGG, grade 1 or 2) that have a mutation called BRAF V600E. This marks the first FDA approval of a […] March 21, 2023